Spago Nanomedical on the progress with Tumorad – Biostock

On January 28, 2022 Spago Nanomedical reported that positive preclinical data in its cancer treatment project Tumorad (Press release, Spago Nanomedical, JAN 28, 2022, View Source [SID1234607471]). After treatment with the candidate 177Lu-SN201, a significant reduction in tumour growth was shown in a colorectal cancer model. In addition, the survival was extended by 39 per cent compared to the control group. BioStock contacted CEO Mats Hansen for a comment on the development work with Tumorad.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In mid-January, First North-listed Spago Nanomedical reported interim results from its clinical study with the tumour-directed contrast agent Spagopix for diagnostics with magnetic resonance imaging. Now, the company is following up with new preclinical data in colorectal cancer in its cancer treatment project Tumorad.

New data provides additional support
Within the Tumorad project, Spago Nanomedical is developing the drug candidate 177Lu-SN201, which is a new radionuclide treatment for aggressive and metastatic cancers. The company’s polymer nanomaterials have been shown to accumulate in tumour tissue and by combining the material with the clinically validated isotope lutetium 177 (177Lu), a local radiation treatment can be carried out in the tumour.

The potential of 177Lu-SN201 is to be able to treat cancers that today are difficult or impossible to access with external radiation or surgery. Spago Nanomedical plans to start the first human studies with the candidate in 2022.

Previously, the company has been able to show positive preclinical data for the candidate in aggressive breast cancer and has now been able to demonstrate efficacy in a preclinical model for colorectal cancer. The study shows that 177Lu-SN201 significantly reduces tumour growth and prolongs survival by 39 per cent compared to the control group.